Local adverse effects ‐ perioperative retinal haemorrhages (unit of analysis: eyes) · preterm infants with type 1 ROP
It is very uncertain whether anti‐vascular endothelial growth factor therapy combined with… changes local adverse effects ‐ perioperative retinal haemorrhages (unit of… compared with laser/cryotherapy (very low certainty).
1 finding from 1 review
Recurrence of ROP by 55 weeks' PMA · preterm infants with type 1 ROP
Anti‐vascular endothelial growth factor therapy combined with… may leads to lower recurrence of ROP by 55 weeks' postmenstrual age compared with laser/cryotherapy (low certainty).
1 finding from 1 review
Overall survival · people with chronic lymphocytic leukaemia
Anti‐CD20 mAb maintenance therapy showed no clear difference in overall survival compared with observation (moderate certainty).
1 finding from 1 review
Overall survival ‐ not reported · people with chronic lymphocytic leukaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life ‐ not reported · people with chronic lymphocytic leukaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Grades 3 and 4 adverse events ‐ not reported · people with chronic lymphocytic leukaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Progression‐free survival · people with chronic lymphocytic leukaemia
It is very uncertain whether anti‐CD52 mAb maintenance therapy changes progression‐free survival compared with observation (very low certainty).
1 finding from 1 review
Treatment‐related mortality ‐ not reported · people with chronic lymphocytic leukaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · people with chronic lymphocytic leukaemia
1 finding from 1 review
Treatment discontinuation · people with chronic lymphocytic leukaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All adverse events – not reported · people with chronic lymphocytic leukaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Grades 3 and 4 adverse events · people with chronic lymphocytic leukaemia
Anti‐CD20 mAb maintenance therapy may leads to higher grade 3/4 adverse events compared with observation (low certainty).
1 finding from 1 review
Progression‐free survival · people with chronic lymphocytic leukaemia
Anti‐CD20 mAb maintenance therapy probably leads to lower progression‐free survival compared with observation (moderate certainty).
1 finding from 1 review
Treatment‐related mortality · people with chronic lymphocytic leukaemia
Anti‐CD20 mAb maintenance therapy showed no clear difference in treatment‐related mortality compared with observation (low certainty).
1 finding from 1 review
Treatment discontinuation · people with chronic lymphocytic leukaemia
Anti‐CD20 mAb maintenance therapy showed no clear difference in treatment discontinuation compared with observation (low certainty).
1 finding from 1 review
All adverse events · people with chronic lymphocytic leukaemia
Anti‐CD20 mAb maintenance therapy may leads to higher all adverse events compared with observation (low certainty).
1 finding from 1 review
Return to normal activities (days) · adolescents and adults with acute fractures in tibia and femur
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to fracture union · adolescents and adults with acute fractures in tibia and femur
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pain (medium term): using VAS (range 0 to 10); higher values indicate worse pain · adolescents and adults with acute fractures in tibia and femur
1 finding from 1 review
Delayed or non‐union (medium term) · adolescents and adults with acute fractures in tibia and femur
It is very uncertain whether extracorporeal shock wave therapy changes delayed or non‐union (medium term) compared with control (very low certainty).
1 finding from 1 review